Novocure LTD 8-K filings

NovoCure's annual shareholder meeting resulted in the election of ten directors and the approval of the 2024 Omnibus Incentive Plan.

NovoCure will present the results of its METIS phase 3 clinical trial for brain metastases from non-small cell lung cancer at the 2024 ASCO Annual Meeting.

NovoCure announced a 13% year-over-year increase in net revenues for Q1 2024, driven by successful launches and improved approval rates, alongside positive clinical trial results.

NovoCure's phase 3 METIS trial demonstrated a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields (TTFields) therapy.

NovoCure reported a 5% decrease in full-year revenue for 2023, but saw a 4% increase in fourth-quarter revenue, and completed key clinical trial enrollments.

The FDA has accepted NovoCure's application for its Tumor Treating Fields therapy in non-small cell lung cancer, marking a significant step towards potential approval.